Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,325 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,671 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06744894 | SIL as Maintenance Therapy in Multiple Myeloma | not yet recruiting | Phase 2 | 50 | Navy General Hospital, BeijingOTHER | 0 | Dec 20, 2024 | clinicaltrials |
| NCT06745193 | A Prospective, Randomized, Open, Phase II Clinical Study of Chidamide in Combination with Camrelizumab and Apatinib for Advanced Esophageal Cancer | not yet recruiting | Phase 2 | 63 | Peking UniversityOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT06739317 | SBRT Combined with Camrelizumab and Apatinib for Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma. | not yet recruiting | Phase 2 / Phase 3 | 398 | Sun Yat-sen UniversityOTHER | 1 | Dec 18, 2024 | clinicaltrials |
| NCT06733233 | A Study Evaluating the Efficacy and Safety of De Trastuzumab (T-DXd) in Combination with Immunotherapy for the Neoadjuvant Treatment of HR-positive HER2 Low-expressing Chinese Patients with Early-stage Breast Cancer | not yet recruiting | Phase 2 | 23 | Guangzhou Women and Children's Medical CenterOTHER | 0 | Dec 13, 2024 | clinicaltrials |
| NCT06731153 | JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC | not yet recruiting | Phase 2 | 40 | Fudan UniversityOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT06728618 | Preoperative Tislelizumab -Cetuximab - Chemotherapy Followed by Salvage Surgery and Adjuvant Tislelizumab -Cetuximab for Resectable, Locally Recurrent Oral and Oropharyngeal Squamous Cell Carcinoma(OSCC) | not yet recruiting | Phase 2 | 28 | Shanghai Zhongshan HospitalOTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT06724263 | A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors | not yet recruiting | Phase 2 | 120 | Tasly Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT06719479 | A Clinical Trial to Evaluate Effect of IAE0972 Combined with Chemotherapy for R/M HNSCC or NPC(Note: It is Currently Phase II.). | not yet recruiting | Phase 2 / Phase 3 | 60 | SUNHO（China）BioPharmaceutical CO., Ltd.INDUSTRY | 0 | Dec 5, 2024 | clinicaltrials |
| NCT06713057 | Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid Cancer | not yet recruiting | Phase 2 | 20 | West China HospitalOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT06714266 | Trilaciclib in Preventing Hematopoietic Suppression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 30 | Shandong Cancer Hospital and InstituteOTHER | 0 | Dec 3, 2024 | clinicaltrials |
| NCT06703047 | Tislelizumab Combined with Chemotherapy and All Trans Retinoic Acid for Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 180 | Fudan UniversityOTHER | 0 | Nov 25, 2024 | clinicaltrials |
| NCT06701344 | Go-CHOP in de Novo Intestinal T-cell Lymphoma Patients(GOAL) | not yet recruiting | Phase 2 | 7 | Ruijin HospitalOTHER | 0 | Nov 22, 2024 | clinicaltrials |
| NCT06699459 | Irinotecan Liposomes +5-FU/LV Versus Capecitabine in Patients of Recurrence After Resection of Resectable BTC(NICRRBTC) | not yet recruiting | Phase 2 | 76 | Sir Run Run Shaw HospitalOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT06699498 | Neoadjuvant Therapy of Targeted Immunotherapy Combined With Chemotherapy for Locally Advanced HNSCC | not yet recruiting | Phase 2 | 45 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT06656221 | A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell Lymphoma | not yet recruiting | Phase 2 | 29 | Ruijin HospitalOTHER | 0 | Nov 19, 2024 | clinicaltrials |
| NCT06694324 | First-line Treatment of Advanced/unresectable DDLPS | not yet recruiting | Phase 2 | 49 | Fudan UniversityOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT06694350 | Pembrolizumab in Combination with Flutamide Treatment for Recurrence / Metastasis HNSCC | not yet recruiting | Phase 2 | 54 | Zhejiang Provincial People's HospitalOTHER | 0 | Nov 19, 2024 | clinicaltrials |
| NCT06690671 | A Single-Arm, Phase Ⅰb Study of Golidocitinib Combined With Anti-PD-1 for the Treatment of Previously Treated NSCLC | not yet recruiting | Phase 1 / Phase 2 | 30 | Shanghai Chest HospitalOTHER | 1 | Nov 15, 2024 | clinicaltrials |
| NCT06684509 | Atorvaststin and Cardiotoxicity in Acute Myloid Leukemia | not yet recruiting | Phase 1 / Phase 2 | 46 | Assiut UniversityOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT06685354 | Sequential T and I With H101 Via HAI for BCLC C Stage HCC: A Prospective Single-Center Single-Arm Pilot Study | not yet recruiting | Phase 2 | 11 | Henan Cancer HospitalOTHER_GOV | 1 | Nov 12, 2024 | clinicaltrials |
| NCT06680115 | Neoadjuvant and Adjuvant Sintilimab Combined with Chemoradiotherapy Versus Chemoradiotherapy Alone in Stage TanyN3M0 Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 150 | First Affiliated Hospital of Guangxi Medical UniversityOTHER | 1 | Nov 8, 2024 | clinicaltrials |
| NCT06681285 | Cadonilimab Combined With Anlotinib Followed by Radiotherapy in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (CAR-RMEC)(CAR-RMEC) | not yet recruiting | Phase 2 | 51 | Hebei Medical University Fourth HospitalOTHER | 1 | Nov 8, 2024 | clinicaltrials |
| NCT06646666 | ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and ASCT | not yet recruiting | Phase 2 | 35 | Ruijin HospitalOTHER | 1 | Nov 1, 2024 | clinicaltrials |
| NCT06669143 | Zanubrutinib-based Maintenance Therapy of Newly Diagnosed DLBCL With Initial Remission | not yet recruiting | Phase 2 | 19 | Ruijin HospitalOTHER | 0 | Nov 1, 2024 | clinicaltrials |
| NCT06654830 | RATT Vs. VATT for Early-stage TETs | not yet recruiting | Phase 2 | 100 | Shanghai Zhongshan HospitalOTHER | 0 | Oct 30, 2024 | clinicaltrials |
| NCT06666166 | SHR-A1811 Combined with Apatinib in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer | not yet recruiting | Phase 2 | 28 | Yunpeng LiuOTHER | 1 | Oct 30, 2024 | clinicaltrials |
| NCT06656559 | Endoscopic Retrograde Cholangiopancreatography With Radiofrequency Ablation (ERCP-RFA) Combined With Envafolimab and Surufatinib Sequential Therapy for Unresectable Biliary Tract Carcinoma | not yet recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Oct 24, 2024 | clinicaltrials |
| NCT06652139 | Selinexor Combined With BEAM for ASCT in R/R DLBCL With MYC Positive | not yet recruiting | Phase 2 | 82 | Ruijin HospitalOTHER | 0 | Oct 22, 2024 | clinicaltrials |
| NCT06652685 | Molecular Subtype Combined with Early Minimal Residual Disease to Optimize the Treatment of Newly Diagnosed Acute Myeloid Leukemia | not yet recruiting | Phase 2 | 218 | Ruijin HospitalOTHER | 1 | Oct 22, 2024 | clinicaltrials |
| NCT06648525 | Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC | not yet recruiting | Phase 2 | 68 | Harbin Medical UniversityOTHER | 1 | Oct 18, 2024 | clinicaltrials |
| NCT06646211 | High-dose Methotrexate Combined with Thiotepa and Zanubrutinib in the Treatment of Newly Diagnosed PCNSL (MTZ) | not yet recruiting | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Oct 17, 2024 | clinicaltrials |
| NCT06641453 | CAR-T Cell Therapy Targeting GPC3 in Patients with Advanced GPC3-Positive Hepatocellular Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT06644313 | Vebreltinib for Neoadjuvant in MET-altered Stage IIIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC) | not yet recruiting | Phase 2 | 31 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Oct 16, 2024 | clinicaltrials |
| NCT06549335 | Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients with Follicular Lymphoma (FL) | not yet recruiting | Phase 2 | 66 | Ruijin HospitalOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06597513 | Auto-HSCT-Supported Dose-Dense Chemotherapy with Adebrelimab As First-Line Treatment for ES-SCLC | not yet recruiting | Phase 1 / Phase 2 | 10 | Zhou ChengzhiOTHER | 0 | Oct 15, 2024 | clinicaltrials |
| NCT06630871 | A Clinical Trial Evaluating the Efficacy and Safety of Disitamab Vedotin Plus Tislelizumab Combined with Re-TURBT in the Treatment of HER-2-high Expression(2+-3+) Non-muscle Invasive Bladder Cancer At High-risk and Very High-risk. | not yet recruiting | Phase 2 | 40 | Fujian Medical University Union HospitalOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT06634667 | Third-generation EGFR-TKI Plus Anlotinib as Maintenance for NSCLC With Small Cell Transformation After EGFR-TKI Resistance | not yet recruiting | Phase 2 | 30 | Hunan Province Tumor HospitalOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT06631040 | Cell Therapy with Anti-CD19 CAR-NK Cells in Patients with Relapsed or Resistant B-ALL | not yet recruiting | Phase 1 / Phase 2 | 10 | Shahid Beheshti University of Medical SciencesOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT06598384 | VA as Maintenance Therapy Post Allo-HSCT in MDS and AML | not yet recruiting | Phase 2 | 40 | Navy General Hospital, BeijingOTHER | 0 | Oct 1, 2024 | clinicaltrials |
| NCT06618391 | Local Injection and Systemic Therapy in the Treatment of NSCLC. | not yet recruiting | Phase 2 | 84 | Henan Cancer HospitalOTHER_GOV | 0 | Oct 1, 2024 | clinicaltrials |
| NCT06620796 | A Phase II Study of Ivonescimab Combined with Cadonilimab and Chemotherapy in Extensive-stage Small Cell Lung Cancer | not yet recruiting | Phase 2 | 70 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Oct 1, 2024 | clinicaltrials |
| NCT06620822 | Efficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical Trial | not yet recruiting | Phase 2 | 296 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT06614231 | Neoajuvant Tislelizumab Combined with Chemotherapy for Initially Unresectable Stage IIIA/N2 Non-small Cell Lung Cancer | not yet recruiting | Phase 2 | 48 | Sun Yat-sen UniversityOTHER | 0 | Sep 26, 2024 | clinicaltrials |
| NCT06614621 | A Study of Adebelimab Combined With Chemotherapy as a First-line Treatment Sequential Treatment for Extensive-stage Small Cell Lung Cancer | not yet recruiting | Phase 2 | 43 | Fujian Cancer HospitalOTHER_GOV | 0 | Sep 26, 2024 | clinicaltrials |
| NCT06611826 | GEP Combined With Radiotherapy in Non-locally Treatable Recurrent NPC | not yet recruiting | Phase 2 | 41 | Zhejiang Cancer HospitalOTHER | 0 | Sep 25, 2024 | clinicaltrials |
| NCT06537297 | Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC With Leptomeningeal Metastases | not yet recruiting | Phase 2 | 30 | Hunan Province Tumor HospitalOTHER | 1 | Sep 20, 2024 | clinicaltrials |
| NCT06497543 | Intrathecal Pemetrexed for SCLC Patients With Refractory Brain Metastases or Leptomeninges Metastatic | not yet recruiting | Phase 2 | 80 | Hunan Province Tumor HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06586866 | JK-1201I in Triple Negative Breast Cancer Patients with Brain Metastases | not yet recruiting | Phase 2 | 25 | JenKem Technology Co., Ltd.INDUSTRY | 0 | Sep 19, 2024 | clinicaltrials |
| NCT06588179 | SHR-1501 Combined With SHR-2005 for High-Risk Non-Muscle Invasive Bladder Cancer Which is Not Completely Resectable by TURBt | not yet recruiting | Phase 1 / Phase 2 | 58 | Fudan UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06588335 | BTLA Inhibitor (JS004) Combined with Toripalimab and Chemotherapy in the Perioperative Treatment of Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 20 | Henan Provincial People's HospitalOTHER | 0 | Sep 19, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Dec 20, 2024source: clinicaltrials